Related Experiment Video

Updated: Jun 22, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer

R M Eager1, C C Cunningham, N Senzer

  • 1Mary Crowley Cancer Research Centers, Dallas, Texas, USA.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 9, 2009
PubMed
Abstract

Insights

Talabostat mesilate did not improve outcomes for advanced non-small cell lung cancer (NSCLC) patients when combined with docetaxel. This phase II trial found no enhanced clinical activity, though the drug was well tolerated.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) has limited treatment options.
  • Talabostat mesilate (PT-100) is an oral dipeptidyl peptidase inhibitor designed to enhance immune response.
  • Fibroblast activation protein (FAP) is a target of talabostat.

Purpose of the Study:

  • To evaluate the efficacy and safety of talabostat mesilate in combination with docetaxel for advanced NSCLC.
  • To determine if talabostat enhances the clinical activity of docetaxel in NSCLC patients post-platinum chemotherapy.

Main Methods:

  • A phase II clinical trial was conducted.
  • 42 patients with advanced NSCLC who failed prior platinum-based chemotherapy were enrolled.
  • Talabostat mesilate was administered in combination with docetaxel.

Main Results:

  • Talabostat mesilate was well tolerated by patients.
  • A partial response was observed in two patients.
  • A complete response was observed in one patient.

Conclusions:

  • Talabostat mesilate did not demonstrate enhanced clinical activity when combined with docetaxel in advanced NSCLC.
  • The combination therapy showed no significant improvement in efficacy compared to docetaxel alone.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...